For Burns

According to the American Burn Association, there are currently over 2,000 cases annually involving burns covering over 50% of the patient’s total body surface area.

Regenicin cultured skin substitute was initially being developed for the treatment of catastrophic, full-thickness burns covering over 30% of the total body surface area. When we applied for Orphan Drug designation from the FDA it was realized that the cultured skin substitute would benefit any burn patient requiring a graft.

Regenicin cultured skin substitute has been used in clinical trials on pediatric patients with catastrophic burns covering from 50 to 90+% of their body.

Regenicin cultured skin substitute is being developed to require less donor skin from the patient’s own body, thus needing fewer surgeries to harvest skin. The result is expected to be less scarring, with fewer infections and faster healing.